Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Eosinophilic gastroenteritis (EGE) is a rare benign gastrointestinal disease characterized by the presence of abnormal and nonspecific gastro-intestinal (GI) manifestations, associated with an eosinophilic infiltration of the GI tract, which can affect several segments and involve several layers within the GI wall.
Biomarker and diagnostic research for eosinophilic gastroenteritis has been reported in the published literature.
No approved treatments are currently available for eosinophilic gastroenteritis. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for eosinophilic gastroenteritis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for eosinophilic gastroenteritis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: 1-9 in 100,000 (Uncommon).
4 clinical trials registered, 3 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
122 publications have been identified in PubMed for eosinophilic gastroenteritis. Research spans Case Report / Case Series (55%), Review / Meta-Analysis (20%), and Epidemiology / Natural History (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 67 |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Benralizumab | Benralizumab | AstraZeneca Pharmaceuticals LP | 2021 | — | Withdrawn |
humanized non-fucosylated Anti-Siglec-8 Monoclonal Antibody (IgG1) | humanized non-fucosylated Anti-Siglec-8 Monoclonal Antibody (IgG1) | Allakos, Inc. | 2018 | — | Withdrawn |
Gene therapy approaches for eosinophilic gastroenteritis have been reported in the published literature.
4 trials found
Research summaries | 25 | 20% |
Disease patterns and progression | 11 | 9% |
Testing and diagnosis research | 7 | 6% |
Clinical study results | 5 | 4% |
Laboratory research | 4 | 3% |
Other research | 2 | 2% |
New treatment approaches | 1 | 1% |
Miyaguchi K (2026). [PMID: 41019197](https://pubmed.ncbi.nlm.nih.gov/41019197/). *DEN open*. [Review / Meta-Analysis]
Muhumed SM (2026). [PMID: 42145803](https://pubmed.ncbi.nlm.nih.gov/42145803/). *Int Med Case Rep J*. [Case Report / Case Series]
Spessotto P (2026). [PMID: 42153131](https://pubmed.ncbi.nlm.nih.gov/42153131/). *Ther Adv Gastrointest Endosc*. [Case Report / Case Series]
Lim WK (2026). [PMID: 42031097](https://pubmed.ncbi.nlm.nih.gov/42031097/). *J Allergy Clin Immunol*. [Clinical Trial Publication]
Qasim A (2026). [PMID: 42083679](https://pubmed.ncbi.nlm.nih.gov/42083679/). *Cureus*. [Case Report / Case Series]
Kakkar C (2026). [PMID: 39899083](https://pubmed.ncbi.nlm.nih.gov/39899083/). *Abdominal radiology (New York)*. [Case Report / Case Series]
Mousa A (2026). [PMID: 41789234](https://pubmed.ncbi.nlm.nih.gov/41789234/). *Annals of medicine and surgery (2012)*. [Case Report / Case Series]
Song H (2026). [PMID: 41743856](https://pubmed.ncbi.nlm.nih.gov/41743856/). *Journal of asthma and allergy*. [Case Report / Case Series]
Li X (2026). [PMID: 41801837](https://pubmed.ncbi.nlm.nih.gov/41801837/). *The American journal of case reports*. [Case Report / Case Series]
Dou M (2026). [PMID: 42021892](https://pubmed.ncbi.nlm.nih.gov/42021892/). *Sichuan Da Xue Xue Bao Yi Xue Ban*. [Review / Meta-Analysis]
AI-curated news mentioning eosinophilic gastroenteritis
Updated Jul 21, 2026
A case study highlights eosinophilic gastroenteritis triggered by egg allergy in a 70-year-old patient. This research contributes to understanding the relationship between food allergies and gastrointestinal disorders.
A recent study highlights an unusual presentation of Salmonella infection, manifesting as cellulitis, gastroenteritis, and bacteremia. This research contributes to the understanding of Salmonella's clinical spectrum and may inform future diagnostic approaches.
A recent study explores epithelial permeability as a dynamic marker in eosinophilic gastroenteritis using probe-based confocal laser endomicroscopy (pCLE). This research may enhance understanding of gut barrier function in this rare disease.
A CDC study reveals that deaths from gastroenteritis more than doubled between 1999 and 2007, highlighting a significant public health concern. This inflammation of the stomach and intestines leads to severe vomiting and diarrhea.